NeuroAid II (MLC901) in Haemorrhagic Stroke

Overview

Journal Case Rep Neurol

Publisher Karger

Specialty Neurology

Date 2021 Jan 28

PMID 33505298

Citations 1

Authors

Chai-Hoon Nowel Tan

David Choy

Narayanaswamy Venketasubramanian

Affiliations

Soon will be listed here.

Abstract

Stroke is a leading cause of death and disability. NeuroAid (MLC601), which originates from Traditional Chinese Medicine, comprises herbal and animal components, and has been shown to improve the functional status of patients after ischaemic stroke. The use of NeuroAid II (MLC901), which comprises only the herbal components of MLC601, in haemorrhagic stroke has not been previously reported. Our patient is a 63-year-old male with a significant stroke risk factor of hypertension. He developed visual field defect, aphasia, unilateral weakness, and hemisensory loss. CT scan showed a left thalamic haemorrhage. In addition to anti-hypertensive therapy and intensive rehabilitation, he was prescribed MLC901. Over a period of 6 months, he had significant improvements in his motor, sensory, and speech function. There were no adverse events, serial brain CT scans showed resolution of the haemorrhage. MLC901 may have a role in post-stroke recovery after intracranial haemorrhage.

Citing Articles

Current neuroprotective agents in stroke.

Yanik T, Yanik B Turk J Phys Med Rehabil. 2024; 70(2):157-163.

PMID: 38948647 PMC: 11209336. DOI: 10.5606/tftrd.2024.15287.

References

Chen C, Venketasubramanian N, Gan R, Lambert C, Picard D, Chan B . Danqi Piantang Jiaonang (DJ), a traditional Chinese medicine, in poststroke recovery. Stroke. 2009; 40(3):859-63. DOI: 10.1161/STROKEAHA.108.531616. View

Yeh M, Chiu W, Wang Y, Lo C . An Investigation of the Use of Traditional Chinese Medicine and Complementary and Alternative Medicine in Stroke Patients. Holist Nurs Pract. 2017; 31(6):400-407. DOI: 10.1097/HNP.0000000000000238. View

Moha Ou Maati H, Borsotto M, Chatelain F, Widmann C, Lazdunski M, Heurteaux C . Activation of ATP-sensitive potassium channels as an element of the neuroprotective effects of the Traditional Chinese Medicine MLC901 against oxygen glucose deprivation. Neuropharmacology. 2012; 63(4):692-700. DOI: 10.1016/j.neuropharm.2012.05.035. View

Shahripour R, Hemati A, Maleki A . A randomized trial to assess the long-term safety of NeuroAiD among Caucasian patients with acute ischemic stroke. Chin J Integr Med. 2014; 20(11):812-7. DOI: 10.1007/s11655-014-1687-8. View

Hemphill 3rd J, Greenberg S, Anderson C, Becker K, Bendok B, Cushman M . Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015; 46(7):2032-60. DOI: 10.1161/STR.0000000000000069. View

Suwanwela N, Chen C, Lee C, Young S, Tay S, Umapathi T . Effect of Combined Treatment with MLC601 (NeuroAiDTM) and Rehabilitation on Post-Stroke Recovery: The CHIMES and CHIMES-E Studies. Cerebrovasc Dis. 2018; 46(1-2):82-88. PMC: 6214602. DOI: 10.1159/000492625. View

Siddiqui F, Venketasubramanian N, Chan E, Chen C . Efficacy and safety of MLC601 (NeuroAiD®), a traditional Chinese medicine, in poststroke recovery: a systematic review. Cerebrovasc Dis. 2013; 35 Suppl 1:8-17. DOI: 10.1159/000346231. View

Stinear C . Prediction of motor recovery after stroke: advances in biomarkers. Lancet Neurol. 2017; 16(10):826-836. DOI: 10.1016/S1474-4422(17)30283-1. View

Young S, Zhao Y, Koh A, Singh R, Chan B, Chang H . Safety profile of MLC601 (Neuroaid) in acute ischemic stroke patients: A Singaporean substudy of the Chinese medicine neuroaid efficacy on stroke recovery study. Cerebrovasc Dis. 2010; 30(1):1-6. DOI: 10.1159/000313398. View

10.

Heurteaux C, Widmann C, Moha Ou Maati H, Quintard H, Gandin C, Borsotto M . NeuroAiD: properties for neuroprotection and neurorepair. Cerebrovasc Dis. 2013; 35 Suppl 1:1-7. DOI: 10.1159/000346228. View

11.

Kong K, Wee S, Ng C, Chua K, Chan K, Venketasubramanian N . A double-blind, placebo-controlled, randomized phase II pilot study to investigate the potential efficacy of the traditional chinese medicine Neuroaid (MLC 601) in enhancing recovery after stroke (TIERS). Cerebrovasc Dis. 2009; 28(5):514-21. DOI: 10.1159/000247001. View

12.

. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019; 18(5):439-458. PMC: 6494974. DOI: 10.1016/S1474-4422(19)30034-1. View

13.

Heurteaux C, Gandin C, Borsotto M, Widmann C, Brau F, Lhuillier M . Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. Neuropharmacology. 2010; 58(7):987-1001. DOI: 10.1016/j.neuropharm.2010.01.001. View